US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Latest News about Lykos Therapeutics

Recent news which mentions Lykos Therapeutics

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
Tickers CMPS NEWS
Tags CT/4201 CMPS mental health
From Benzinga
Veterans Affairs Eyes Funding For New MDMA-PTSD Trial After FDA Setback
Tickers NEWS
Tags News Benzinga Shereef Elnahal
From Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Tickers ATAI CMPS DMT MBIO
Tags Regulations DMT Compass Pathways
From Benzinga
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Tickers CMPS NEWS
Tags Multidisciplinary Association for Psychedelic Studies (MAPS) Michael Mullette CMPS
From Benzinga
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Tickers NEWS
Tags Rick Dolbin Psychedelics Jeff George
From Benzinga
MDMA Therapy Papers Retracted Amid Ethical Concerns At Lykos Study Site
Tags Food and Drug Administration Market News Psychedelic Research
From Benzinga
FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
Tickers MDMA NEWS
Tags Psychedelics MDMA Legal
From Benzinga
FDA Poised To Make Historic Decision On MDMA Therapy To Treat PTSD: Here's How Things Stand
Tickers MDMA NEWS
Tags Food and Drug Administration Psychedelic Assisted Therapies Market News
From Benzinga
Five Out Of Six Studies On MDMA Show Positive Results, Yet FDA Approval Still Faces Hurdles
Tickers NEWS
Tags Cannabis PTSD Benzinga
From Benzinga
MDMA Therapy For PTSD Closer To Legality As Key FDA Approval Meeting Approaches, Sparking Hope And Controversy
Tickers NEWS
Tags Government Lykos Therapeutics Veterans Administration
From Benzinga